Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 12

  • 356 clinical trials
  • 141 recruiting
  • 239 conditions
  • 25 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis13Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

356 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

356 clinical trials

Hepato-lenticular degeneration

Recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Hepatic fibrosis

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Biliary neoplasm

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione GONO G.I.

Alpha-1 antitrypsin deficiency

Recruiting
InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Endometrial cancer+38

Recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ds-3939A
  • Sponsor:Daiichi Sankyo Inc.

Alcoholic liver disease

Recruiting
Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Hepatocellular carcinoma

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Hepatocellular carcinoma

Recruiting
Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Universitair Medisch Centrum Groningen

Metabolic dysfunction-associated steatohepatitis+1

Recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Namodenoson
  • Sponsor:Can-Fite Biopharma Ltd.

Hepatic cirrhosis+1

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tinzaparin Sodium
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Autoimmune hepatitis

Not yet recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Hepatocellular carcinoma

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.